Oryzon anuncia buenos datos finales de PORTICO y se reúne con la FDA para una Fase III
Oryzon has released the final data from the PORTICO trial, confirming significant improvements in the treatment of Borderline Personality Disorder with vafidemstat. These results strengthen its case before the FDA, potentially accelerating the transition to Phase III and consolidating its unique position in a therapeutic area lacking approved drugs. The clinical success, coupled with recent patent grants, highlights the substantial economic potential and viability of this innovative therapeutic program. This news is relevant to open data because it underscores the importance of transparency in clinical trials. Sharing Phase II data enables the scientific community to validate findings and accelerate the development of treatments for neglected disorders, fostering open collaboration.
Source: bolsamania.comPublished on 2024-09-24
Related news
- Incendios forestales en Brasil provocan mayor nivel de emisiones de carbono en dos décadas - Mundo - ABC Color
- Las pernoctaciones hoteleras bajan un 0,9% en agosto en C-LM, que registra un 1,42% más de turistas
- Biden plantea prohibir los vehículos que tengan tecnología china y rusa
- The AI Danger Zone: ‘Data Poisoning’ Targets LLMs
- Province reports high volume of Freedom of Information requests for 2023-24 – haligonia.ca